NDAORALTABLET
Approved
Feb 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
ANTIVERT (meclizine hydrochloride) by R-Pharm US is h1 receptor. Approved for vertigo associated with diseases affecting the vestibular system in adults. First approved in 1957.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTIVERT (meclizine hydrochloride) is an oral H1 receptor antagonist tablet approved in 1957 for treating vertigo associated with vestibular system diseases in adults. It works by blocking histamine H1 receptors, which reduces inner ear sensitivity and alleviates dizziness and nausea. This is a well-established, first-line symptomatic treatment for balance disorders.
$0.002BPart D
LOE ApproachingLOE approaching with minimal Part D penetration signals mature, stable product with shrinking promotional infrastructure and limited growth opportunities for brand teams.
Mechanism of Action
H1 receptor.
Career Relevance
Working on ANTIVERT offers limited career growth potential due to its LOE-approaching status and minimal linked job openings (0). Roles are primarily focused on defending market share, managing generic competition, and ensuring compliance rather than driving innovation or expansion.
Brand Manager
Worked on ANTIVERT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.